Pharmaceutical Company CEO Developing $100 Alternative To EpiPen After 'Shameful' Price Hike
September 4, 2016
Mark Baum, CEO of Imprimis Pharmaceuticals who previously came out with a $1 alternative to Martin Shkreli's AIDS drug after 5000% price hike, is now going to take on Mylan and is plotting to offer a $100 EpiPen alternative.
Mark Baum / Imprimis Pharmceuticals
Baum believes the relentless EpiPen price hikes are "shameful" and plans to have a compounded version of the allergy treatment by the end of the year.
"I don't need to make $19 million a year," Baum said, referring to the big pay package Mylan's CEO Heather Bresch took home last year.
"Tonight when I go home I'm going to eat a nice piece of fish and the fish I eat isn't any better or worse than what she is going to eat."
Click Here For The Most Popular On Sunny Skyz
Boy With Down Syndrome Nails The Whitney Houston Challenge, And The Crowd Goes Wild
Lowe’s Staff Refuse To Give Up On Missing Cat, Find Her 85 Miles Away
The ‘Grandma Stand’ Is Bringing Comfort And Connection, One Conversation At A Time
Husband Rents Mall Store To Share His Late Wife's Beloved Christmas Display
This Priest Secretly Became A Masked Wrestler To Fund An Orphanage
The Kindness Continues For These Two Kings Who Went Viral
A Struggling Mom Could Not Stop Crying After A Stranger’s Christmas Gift
She Was Ready For A Fight With Her Neighbor. His Response Changed Everything
Texans Owner Gets Left Hanging On Live TV — What The Media Team Did Next Is Hilarious
Trail Cam Reveals Secret Meeting Spot For Wild Animals
After 2 Years Apart, Siblings In Foster Care Are Finally Reunited
